Enliven Therapeutics (ELVN) Competitors $18.73 -0.08 (-0.43%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.72 -0.02 (-0.08%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN vs. CYTK, MRUS, KRYS, AKRO, RNA, ADMA, SRRK, ACAD, PTCT, and ZLABShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Cytokinetics (CYTK), Merus (MRUS), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), Avidity Biosciences (RNA), ADMA Biologics (ADMA), Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), PTC Therapeutics (PTCT), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. Its Competitors Cytokinetics Merus Krystal Biotech Akero Therapeutics Avidity Biosciences ADMA Biologics Scholar Rock ACADIA Pharmaceuticals PTC Therapeutics Zai Lab Cytokinetics (NASDAQ:CYTK) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Is CYTK or ELVN more profitable? Enliven Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -3,201.47%. Cytokinetics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-3,201.47% N/A -43.75% Enliven Therapeutics N/A -31.84%-30.09% Do analysts prefer CYTK or ELVN? Cytokinetics presently has a consensus price target of $70.92, suggesting a potential upside of 93.30%. Enliven Therapeutics has a consensus price target of $41.20, suggesting a potential upside of 119.97%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than Cytokinetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.88Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of CYTK or ELVN? 95.1% of Enliven Therapeutics shares are owned by institutional investors. 2.7% of Cytokinetics shares are owned by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, CYTK or ELVN? Cytokinetics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Which has preferable earnings and valuation, CYTK or ELVN? Enliven Therapeutics has lower revenue, but higher earnings than Cytokinetics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$18.47M237.24-$589.53M-$5.29-6.94Enliven TherapeuticsN/AN/A-$89.02M-$1.92-9.76 Does the media favor CYTK or ELVN? In the previous week, Cytokinetics had 8 more articles in the media than Enliven Therapeutics. MarketBeat recorded 11 mentions for Cytokinetics and 3 mentions for Enliven Therapeutics. Cytokinetics' average media sentiment score of 0.63 beat Enliven Therapeutics' score of 0.48 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryEnliven Therapeutics beats Cytokinetics on 9 of the 16 factors compared between the two stocks. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$922.99M$2.46B$5.48B$9.51BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-9.768.9728.6723.80Price / SalesN/A437.63373.9066.58Price / CashN/A157.7635.4557.96Price / Book2.954.838.275.55Net Income-$89.02M$31.62M$3.24B$259.03M7 Day Performance-11.65%-5.28%-3.69%-4.59%1 Month Performance-9.25%4.38%4.33%4.46%1 Year Performance-19.34%-2.49%25.95%18.03% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics2.469 of 5 stars$18.73-0.4%$41.20+120.0%-24.2%$922.99MN/A-9.7650CYTKCytokinetics4.0154 of 5 stars$36.96-0.7%$70.92+91.9%-36.6%$4.45B$18.47M-6.99250News CoverageUpcoming EarningsAnalyst ForecastInsider TradeMRUSMerus2.9208 of 5 stars$62.37-1.4%$84.64+35.7%+25.1%$4.38B$54.73M-15.2937News CoverageKRYSKrystal Biotech4.8885 of 5 stars$148.09+0.4%$213.75+44.3%-21.0%$4.26B$290.52M35.60210Upcoming EarningsAKROAkero Therapeutics3.9641 of 5 stars$51.38-1.3%$82.50+60.6%+83.6%$4.15BN/A-26.3530Positive NewsUpcoming EarningsRNAAvidity Biosciences2.7815 of 5 stars$34.02+0.8%$66.35+95.0%-19.4%$4.07B$10.90M-11.34190News CoverageUpcoming EarningsADMAADMA Biologics4.2926 of 5 stars$17.13+2.4%$27.67+61.5%+57.7%$3.99B$426.45M20.15530Upcoming EarningsSRRKScholar Rock3.8123 of 5 stars$41.12+1.0%$42.67+3.8%+301.3%$3.87B$33.19M-16.25140News CoveragePositive NewsUpcoming EarningsAnalyst ForecastACADACADIA Pharmaceuticals4.0001 of 5 stars$22.28-1.2%$27.88+25.1%+23.9%$3.78B$996.28M16.26510News CoverageUpcoming EarningsAnalyst RevisionPTCTPTC Therapeutics4.4836 of 5 stars$47.86+0.5%$65.00+35.8%+59.5%$3.78B$1.77B7.351,410Trending NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionZLABZai Lab2.217 of 5 stars$34.66+3.2%$54.28+56.6%+99.7%$3.73B$398.99M-13.921,869News CoveragePositive NewsUpcoming EarningsShort Interest ↑Gap Up Related Companies and Tools Related Companies Cytokinetics Competitors Merus Competitors Krystal Biotech Competitors Akero Therapeutics Competitors Avidity Biosciences Competitors ADMA Biologics Competitors Scholar Rock Competitors ACADIA Pharmaceuticals Competitors PTC Therapeutics Competitors Zai Lab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELVN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
